Repro Med Systems Stock Today
| KRMD Stock | USD 2.92 0.02 0.69% |
PerformanceVery Weak
| Odds Of DistressLow
|
Repro Med is trading at 2.92 as of the 20th of March 2025, a 0.69 percent increase since the beginning of the trading day. The stock's lowest day price was 2.78. Repro Med has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 20th of March 1996 | Category Healthcare | Classification Health Care |
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. The company has 45.96 M outstanding shares of which 375.93 K shares are now shorted by private and institutional investors with about 1.95 trading days to cover. More on Repro Med Systems
Moving together with Repro Stock
Moving against Repro Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Repro Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Linda Tharby | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRepro Med can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Repro Med's financial leverage. It provides some insight into what part of Repro Med's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repro Med Systems (KRMD) is traded on NASDAQ Exchange in USA. It is located in 100 Corporate Drive, Mahwah, NJ, United States, 07430 and employs 82 people. Repro Med is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 133.28 M. Repro Med Systems conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 45.96 M outstanding shares of which 375.93 K shares are now shorted by private and institutional investors with about 1.95 trading days to cover.
Repro Med Systems currently holds about 18.27 M in cash with (319.72 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Check Repro Med Probability Of Bankruptcy
Ownership AllocationRepro Med owns a total of 45.96 Million outstanding shares. Over half of Repro Med's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Repro Ownership Details
Repro Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| White Pine Capital Llc | 2024-12-31 | 157.9 K | |
| State Street Corp | 2024-12-31 | 135.6 K | |
| Washington Trust Co | 2024-12-31 | 100 K | |
| Pnc Financial Services Group Inc | 2024-12-31 | 97 K | |
| Empire Financial Management Company, Llc | 2024-12-31 | 95 K | |
| 683 Capital Management Llc | 2024-12-31 | 88.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 86.3 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 83.9 K | |
| Northern Trust Corp | 2024-12-31 | 79.2 K | |
| First Light Asset Management, Llc | 2024-12-31 | 5.9 M | |
| Topline Capital Management Llc | 2024-12-31 | 4.3 M |
Repro Med Historical Income Statement
Repro Stock Against Markets
Repro Med Corporate Management
| Brian Case | Chief Officer | Profile | |
| Thomas Adams | Chief Officer | Profile | |
| Rob Cannon | Vice Sales | Profile | |
| Josh Bennett | VP Devel | Profile | |
| Kenneth Miller | Chief Officer | Profile | |
| Tom Adams | Interim Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.13) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.